Clinical Development

Our clinical development group is comprised of experienced professionals with expertise and experience to quickly move our development candidate compounds from preclinical testing to investigational new drug (IND) status and through Phase III clinical trials. The development group possesses critical expertise in the areas of chemistry, manufacturing and controls (CMC), pre-clinical testing, clinical trial design, management and analysis, and regulatory affairs. The team's proficiency and productivity is a remarkable asset that has enabled us to advance twelve compounds from lead candidate to the clinic in three years.

The critical mass and speed of our research and discovery operations generates significant momentum toward the clinic. We intend to build a similar critical mass of clinical data that will carry our product candidates toward the market. Our strategy is to conduct rigorous and extensive Phase II clinical programs that explore the utility of our compounds in a variety of indications, in combination or comparison with other regimens and in various dosing schedules. These extensive Phase II clinical trial programs will enable us to make data driven decisions about how to advance our compounds into pivotal registration trials.